Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...